跳至主要内容
临床试验/NCT01148836
NCT01148836已完成不适用

Coenzyme Q-10 in the Treatment of Pulmonary Arterial Hypertension

The Cleveland Clinic1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2010年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
18
试验地点
1
主要终点
Left Ventricular End Diastolic Volume

研究概览

简要总结

The purpose of this study is to evaluate the effects of Coenzyme Q-10, an antioxidant, in the treatment of pulmonary hypertension.

详细描述

Abnormalities in the blood vessels in the lung are the hallmark of pulmonary hypertension. Links between increased free radical production, mitochondrial dysfunction and pulmonary hypertension have been studied but are poorly understood. The mitochondria of cells is the location where cellular energy is created and free radicals are atoms or groups of atoms with an odd (unpaired) number of electrons and can be formed when oxygen interacts with certain molecules. Once formed these reactive radicals can start a chain reaction, like dominoes. Their chief danger comes from the damage they can do when they react with important cellular components. Cells may function poorly or die if this occurs. The body produces free radicals in the normal course of energy production and in pulmonary hypertension, free radical production is found to be increased. To prevent free radical damage the body has a defense system of antioxidants. Coenzyme Q-10 is an antioxidant and it helps to protect cells from damage caused by the body's own free radicals. By providing oral supplementation of coenzyme Q-10, free radical levels will be decreased and cellular functioning in the pulmonary blood vessels may improve and even return to near normal functioning.

The purpose of this study is to evaluate the effects of coenzyme Q-10, an antioxidant, in the treatment of pulmonary hypertension. We will assess coenzyme Q-10 supplementation in the treatment of pulmonary hypertension by clinical measurements and blood levels of certain cellular components. We would like to assess the effects of coenzyme Q-10 on the pulmonary vessels by measuring the lung diffusing capacity (a breathing test) and exhaled Nitric Oxide (NO) (a substance in the body that relaxes or dilates blood vessels). We will also measure endothelial progenitor cells (cells from the bone marrow) from a blood sample; these cells are markers of measure of blood vessel formation and repair. We will also measure the activity of superoxide dismutase (a protein in cells that executes the breakdown of a free radical into oxygen and hydrogen peroxide) in the blood. In addition, we will measure levels of coenzyme Q-10 in the blood. Other markers of disease response to therapy will be done including physical exam, BNP level (a blood marker that correlates with heart function), 6-minute walk and echocardiography (ultrasound of the heart). A total of 60ml (5 tablespoons) of blood will be drawn at each visit.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Males and Females age equal to or greater than 18 not to exceed
  • •Patients with PAH Class 1 (Venice 2003)
  • •PAH medications must not have changed for the last two months.
  • •Women of child-bearing age must use a double-barrier local contraception until completion of study.
  • •Subjects must demonstrate understanding of study and sign informed consent and have a reliable method of communication for contact and the ability to comply with the study requirements.

排除标准

  • •Participation in any other studies at the time of enrollment
  • •History of any significant illness within four weeks of starting Coenzyme Q-10
  • •Hepatic insufficiency (transaminase levels >4 fold the upper limit of normal or bilirubin >2 fold the upper limit of normal).
  • •Renal insufficiency (creatinine >2)
  • •Pregnancy,breast-feeding or lack of safe contraception.
  • •Acute heart failure
  • •Known allergy to the study drug or drugs similar to the study drug
  • •History of drug or alcohol abuse within last 12 months

研究组 & 干预措施

Coenzyme Q 10 and Pulmonary Hypertension

Experimental

PAH subjects to take Co-Q daily for three months

干预措施: Coenzyme Q-10 in Pulmonary Hypertension subjects (Dietary Supplement)

Coenzyme Q 10 and Normal Controls

Experimental

Normal controls to take Co-Q daily for three months

干预措施: Coenzyme Q-10 in Normal Control subjects (Dietary Supplement)

结局指标

主要结局

Left Ventricular End Diastolic Volume

时间窗: before and after three months of CoQ

Amount of blood in ventricle at end of diastole

Right Ventricular Outflow

时间窗: before and after three months of CoQ

Velocity time interval

Right Ventricle Myocardial Performance

时间窗: before and after three months of CoQ

Tei Index=(IRT+ICT)/ET, where IRT is isovolumic

Tricuspid Regurgitation Grade

时间窗: before and after three months of CoQ

Tricuspid Regurgitation Grade ranges from 1 (normal) to 4 (severe regurgitation)

Right Atrial Pressure

时间窗: before and after three months of CoQ

次要结局

  • Hemoglobin(before and after three months of CoQ)
  • Red Blood Cells(before and after three months of CoQ)
  • Hematocrit(before and after three months of CoQ)
  • Red Blood Cell Distribution Width(before and after three months of CoQ)
  • Mean Corpuscular Hemoglobin(before and after three months of CoQ)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jacqueline Sharp

Nurse Practitioner

The Cleveland Clinic

研究点 (1)

Loading locations...

相似试验